Hints and tips:
...The deal is Pfizer’s largest since its 2016 purchase of Medivation for $14.3bn....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...Pfizer on Tuesday raised $31bn in a jumbo-sized bond sale that will help fund the takeover....
...The drugmakers Pfizer and Roche said they are piloting use of rFC at some of their facilities....
...Haleon declined to comment on Pfizer’s plans....
...Pfizer believes that in 2030 Seagen could contribute more than $10bn in risk-adjusted revenues....
...The EU is renegotiating its vaccine contract with BioNTech/Pfizer, which has raised concerns among rivals that it could push them out of the lucrative market....
...Shares in oncology-focused biotech Seagen, which Pfizer has agreed to buy for $43bn, also fell amid fears the agency could target other deals in the sector....
...The downbeat forecasts contrast with a stellar performance by Pfizer in 2022. Pfizer reported earnings per share of $6.58 in 2022, a record for the 174-year-old company....
...Pfizer’s expertise in mRNA — the core technology used in the Covid vaccine — also provides opportunities, he added. But in the short term, Pfizer is reliant on its existing pipeline....
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...Liu said Pfizer would not want to “damage their global price integrity” by reducing the price for China. “Pfizer cannot sacrifice the global market for China,” he added....
...Illumina’s market capitalisation is roughly $33bn, about a quarter of Amgen’s and well below Pfizer’s $246bn valuation....
...Eli Lilly, Amgen, Pfizer and Regeneron are among the companies aiming to compete with market leader Novo Nordisk in a category which analysts say is rapidly becoming a healthcare priority and could produce...
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Pfizer shares were up 2.7 per cent to $47.80 just after midday in New York trading Tuesday....
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...“From a public health point of view I think we’re doing important things and I think that will translate to revenues and a return to Pfizer,” William Gruber, senior vice-president of Pfizer vaccine clinical...
...Pfizer is also studying whether its shot can prevent RSV infection in infants from birth up to six months of age by vaccinating pregnant women....
...The Federal Reserve is set to raise interest rates by 0.75 points for the fourth time in a row, and Pfizer raised its sales forecast for its Covid-19 vaccine by $2bn to $34bn on Tuesday....
...by both BioNTech and Pfizer,” the company said in a statement....
...Albert Bourla, chief executive of Pfizer, said the agility of BioNTech/Pfizer’s mRNA platform and their extensive clinical experience with Covid vaccines had enabled the companies to develop, test and manufacture...
...Pfizer said it would make a $25mn milestone payment to Valneva on initiation of the phase 3 clinical study....
...Over the following four years, Pfizer and Flynn pushed prices up sharply. Pfizer charged prices between 780 and 1,600 per cent higher than previously....
...Pfizer could revisit its bullish manufacturing plans to tackle any supply glut, he added....
International Edition